Cancer-promoted genetic events and related genes (or so-called driver mutations and driver genes) have been not only successfully identified in most types of cancer but also linked to novel therapeutic opportunities, such as EGFR mutations to lung cancer, BRAF mutations to melanoma, and KIT mutations to gastrointestinal stromal tumors1,2. This evidence concerns the gene EGFR and cancer.